Compare HOPE & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HOPE | ANIP |
|---|---|---|
| Founded | 1986 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.9B |
| IPO Year | 2000 | 1999 |
| Metric | HOPE | ANIP |
|---|---|---|
| Price | $13.43 | $73.23 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 9 |
| Target Price | $15.50 | ★ $105.78 |
| AVG Volume (30 Days) | ★ 666.2K | 308.3K |
| Earning Date | 10-27-2026 | 11-06-2026 |
| Dividend Yield | ★ 4.21% | N/A |
| EPS Growth | N/A | ★ 419.23 |
| EPS | 0.49 | ★ 2.32 |
| Revenue | N/A | ★ $206,547,000.00 |
| Revenue This Year | $24.46 | $25.00 |
| Revenue Next Year | $22.15 | $11.39 |
| P/E Ratio | ★ $27.39 | $31.23 |
| Revenue Growth | N/A | ★ 2.47 |
| 52 Week Low | $9.80 | $69.58 |
| 52 Week High | $14.59 | $96.99 |
| Indicator | HOPE | ANIP |
|---|---|---|
| Relative Strength Index (RSI) | 29.17 | 46.02 |
| Support Level | $13.09 | $69.87 |
| Resistance Level | $13.29 | $83.03 |
| Average True Range (ATR) | 0.26 | 2.38 |
| MACD | -0.08 | 0.01 |
| Stochastic Oscillator | 2.70 | 32.59 |
Hope Bancorp Inc is a bank holding company engaged in providing financial services. It offers core business banking products for small and medium-sized businesses and individuals. Services offered by the bank include online banking, mobile banking, mortgage loans, credit cards, investment and wealth management services, and other banking services.
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.